Pathogenic Priming in COVID-19: Six Years of Disease
Presentation on Monday, 3/16/2026 by our Founder and President - IPAK-EDU Director's Science Webinar featuring Dr. James Lyons-Weiler
This 60-minute scientific review examines a hypothesis first proposed in early 2020 by the Institute for Pure and Applied Knowledge (IPAK): that proteins encoded by SARS-CoV-2—particularly the spike glycoprotein—contain immunogenic epitopes with homology to human proteins and could therefore trigger autoimmune disease through molecular mimicry and immune dysregulation. Published weeks into the pandemic and before any vaccine existed, the framework further proposed the concept of pathogenic priming, predicting that immune responses generated against viral spike protein might in susceptible individuals initiate multi-organ autoimmunity. The presentation evaluates whether predictions made at the beginning of the pandemic have been supported, refined, or contradicted by five years of subsequent research.
The talk begins by placing the concept of virus-induced autoimmunity within historical precedent, highlighting well-established examples such as Epstein-Barr virus in multiple sclerosis, Campylobacter infection in Guillain-Barré syndrome, and the 2009 H1N1 influenza vaccine-associated narcolepsy linked to hypocretin receptor mimicry. Pre-pandemic vaccine studies of SARS and MERS are also reviewed to show that immune-mediated pathology following spike exposure had already been documented in animal models, establishing the empirical basis for concern about coronavirus spike immunogenicity.
Viewed in this context, the Pathogenic Priming hypothesis sits, unfortunately, as the hypothesis now well tested and validated by the largest natural experiment ever assembled for studying viral induction of autoimmunity, with hundreds of millions of infections and unprecedented global surveillance of immune-mediated disease.
A critical evidence-level interpretive framework is introduced early and carried throughout the presentation. Four distinct evidence tiers are defined: anti-spike antibodies as exposure markers, autoantibodies against host proteins, functional autoantibodies confirmed by bioassay, and nucleic acid detection of viral or vaccine-derived genetic material. These represent fundamentally different levels of evidentiary strength and must not be conflated. Many disputes in the COVID autoimmunity literature arise from collapsing these categories—either overstating weak associations or dismissing stronger mechanistic findings.
The presentation then revisits the seminal and foundational April 2020 IPAK study of the SARS-CoV-2 proteome. The investigation combined immunogenic epitope prediction (SVMTriP), short-sequence homology searches optimized for immune recognition windows (p-BLAST), pathway mapping through Reactome, and tissue-expression data from the Human Protein Atlas. The analysis identified immunogenic epitopes in 29 of 37 viral proteins with homology to human proteins involved in immune regulation, cardiac function, neurological signaling, endocrine biology, and vascular physiology. Notably, more than 40 percent of the matched targets were components of the adaptive immune system itself, including B-cell receptors, T-cell receptor β chains, and immunoglobulin junction regions.
Specific predicted host targets identified in the original analysis—including titin, GRIK2, SORCS1, and S100A10—are examined retrospectively against the subsequent literature. The findings generated a central prediction: exposure to spike protein, whether through infection or vaccination, could in susceptible individuals trigger pathogenic priming leading to multi-organ autoimmunity.
The remainder of the presentation reviews the extensive body of research that emerged between 2020 and 2026 testing this hypothesis. Early experimental validation came from studies confirming cross-reactivity between antibodies raised against SARS-CoV-2 proteins and multiple human tissue antigens. Subsequent large-scale profiling platforms screened thousands of extracellular human proteins against patient antibodies and reported widespread autoantibody production in COVID-19 patients. Functional validation experiments in animal models showed that certain autoantibodies could directly increase disease severity, moving the field from theoretical plausibility toward mechanistic confirmation of pathogenic priming.
Longitudinal cohort studies subsequently demonstrated that many patients develop new autoantibodies weeks to months after infection and that these antibodies can persist for more than a year. These findings indicate sustained immune dysregulation rather than transient immune activation and suggest that SARS-CoV-2 infection can remodel immune regulation in a subset of individuals.
A major advance highlighted in the talk is the independent discovery of a different form of pathogenic priming: the generation of functional autoantibodies targeting G-protein-coupled receptors (GPCRs). Generated through bystander B-cell activation rather than sequence mimicry, these antibodies target β-adrenergic, muscarinic, and angiotensin receptors and have been shown by cardiomyocyte bioassay to alter receptor signaling directly. They are strongly associated with dysautonomia, tachycardia, fatigue, and orthostatic intolerance and have been identified in long COVID, myalgic encephalomyelitis/chronic fatigue syndrome, and post-vaccination syndromes. These findings represent one of the most clinically actionable discoveries in the field and have led to targeted therapeutic trials.
Another critical area explored is antigen persistence. Several studies have detected spike protein or viral genetic material in blood, lymphoid tissue, gut mucosa, and vascular tissues months after infection. Such persistence may provide the antigenic stimulus necessary to sustain autoimmune activation long after the acute infection has resolved. In some cases, sequence-confirmed persistence of vaccine-related genetic material has been documented years after vaccination, demonstrating that long-term retention is biologically possible even if its population frequency remains unknown.
The presentation surveys the clinical spectrum of the predicted post-COVID and post-vaccine autoimmune disease across multiple organ systems, including cardiovascular, neurological, endocrine, hematologic, renal, hepatic, dermatologic, and rheumatologic conditions. Large epidemiological studies—including analyses of multi-million patient health-record networks—provide the population-level frame. Vaccine-induced thrombotic thrombocytopenia (VITT) is discussed as an important large signal: an established post-vaccination autoimmune condition caused by adenoviral vector vaccines through anti-PF4 antibodies and not by spike mimicry. This example illustrates the importance of distinguishing among different mechanisms of immune-mediated pathology.
A retrospective validation analysis then compares the predictions made in 2020 with the evidence accumulated over five years. Several core IPAK predictions—including multi-organ autoimmunity associated with spike exposure, adaptive immune dysregulation, thyroid involvement, and cardiac pathology consistent with titin targeting—are supported by subsequent research, while other predictions remain consistent with emerging data but require additional confirmation.
At the same time, the field has uncovered mechanisms that were not anticipated by the original study. These include functional GPCR autoantibodies, extracellular vesicle transport of spike protein enabling distal tissue distribution, Epstein-Barr virus reactivation as a secondary driver of immune dysregulation, and ribosomal frameshifting associated with modified mRNA constructs that may generate previously unrecognized peptides.
These discoveries contribute to a unifying mechanistic model in which three major pathogenic priming pathways operate simultaneously following spike exposure: molecular mimicry generating organ-specific autoantibodies, bystander B-cell activation generating GPCR functional autoantibodies and broad autoantibody repertoires, and direct spike–ACE2 structural interactions producing vascular and endothelial pathology independent of adaptive immunity. Antigen persistence may extend the activity of all three pathways beyond the acute phase of infection.
Taken together, these findings suggest that SARS-CoV-2 exposure—whether through infection or spike-based vaccination—can activate multiple immunological pathways capable of producing autoimmune disease in susceptible individuals, though the magnitude and population-level risk differ between exposure routes.
The therapeutic implications of this framework are then examined. Because long COVID (and long vax) likely represents multiple overlapping biological mechanisms rather than a single disease entity, effective treatment requires matching intervention to mechanism. Potential strategies include antivirals targeting viral persistence, immunoadsorption or antibody-neutralizing therapies targeting pathogenic autoantibodies, and immune-modulating drugs addressing downstream inflammatory dysregulation. The presentation argues that many clinical trials have failed not because treatments are ineffective but because patient populations were not stratified according to underlying biological mechanisms. Biomarker-guided trial designs—such as studies enrolling only patients with GPCR autoantibodies—are presented as the methodological path forward.
The talk concludes that five years of research have, unfortunately, overwhelmingly validated the original pathogenic priming hypothesis and has expanded the mechanisms. COVID-19 has revealed a complex network of immune-mediated pathologies linking viral infection, antigen persistence, autoantibody generation, and systemic inflammation. The pandemic has therefore produced the largest natural experiment ever observed in viral autoimmunity. Insights emerging from this unprecedented dataset are likely to influence future vaccine design, pandemic preparedness, and the broader scientific understanding of post-viral syndromes and autoimmune disease.
As we warned in April 2020, no future vaccines should be developed without first screening for unsafe epitopes.
The CDC — the Centers for Disease CONTROL and Prevention — rarely speaks about true prevention in the way most people imagine it. The prevailing narrative suggests that getting sick activates the immune system and builds protection against future illness. In other words, illness is framed as inevitable — even necessary.
That premise assumes pathogens will always be present and that exposure leading to illness is simply part of life. It assumes we must get sick to become stronger. It assumes pharmaceutical intervention is the primary solution.
But what if that assumption is outdated?
What if prevention is not only possible — but practical, inexpensive, and scalable?
Modern healthcare largely operates on a reaction model: identify illness, treat symptoms, manage outcomes. Pharmaceutical products ease discomfort and reduce severity, but they do not eliminate the root cause — pathogen exposure in our daily environments.
Pathogen load can be reduced.
Homes, workplaces, and schools can be disinfected more effectively. Environmental hygiene can be improved without relying solely on chemical residues. Ozone water, for example, is used across multiple industries as a powerful disinfectant that leaves no chemical residue because it reverts back to oxygen.
When environmental pathogen exposure is reduced, the immune system is not constantly forced into defensive mode. The immune system does not disappear — it simply isn’t under continuous assault. Energy that would have been spent responding to repeated exposures can instead support repair, recovery, and overall vitality.
The conventional model says illness is unavoidable. I disagree. If exposure is minimized, illness becomes far less likely.
I’m approaching ten years without sick time — no vaccines, flu shots, or cold medications. For many people, that sounds unrealistic. But perhaps what’s unrealistic is the assumption that annual illness is normal and inevitable.
Prevention deserves more discussion.
Pharmaceutical companies profit when illness exists. That is not controversial — it is how the business model works. Revenue requires patients. Treatment requires disease. Incentives shape systems.
Pharma companies fund research, support medical schools, advertise heavily, donate politically, and influence policy. That influence shapes which solutions are prioritized and which are ignored.
Ozone water is widely used in industrial sanitation, food processing, and pharmaceutical clean rooms because it is an effective disinfectant. Yet it is rarely discussed in mainstream healthcare conversations about prevention.
Why?
If broad environmental pathogen reduction became common practice, demand for certain reactive treatments could decline. That would disrupt established financial structures.
Control and prevention are not the same thing.
Prevention focuses on eliminating or reducing exposure to root causes. Control focuses on managing outcomes once exposure has already occurred.
Perhaps it is time to reconsider the premise that getting sick is simply unavoidable.
Learning how to properly disinfect personal spaces — including the safe and appropriate use of ozone water — can be part of a broader strategy to reduce infection risk and improve resilience.
Getting sick may not be as inevitable as we’ve been told.
This might explain how coronaviruses cause bronchitis.